Ginkgo Bioworks Holdings, Inc. is a biotech company. The company is headquartered in Boston, Massachusetts and currently employs 834 full-time employees. The company went IPO on 2021-04-19. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatics support services, offered to both government and non-government customers through its two core offerings: Canopy and Horizon. The firm provides comprehensive research and development services spanning the genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics.
Follow-Up Questions
Ginkgo Bioworks Holdings Inc의 CEO는 누구입니까?
Dr. Jason Kelly은 2021부터 회사에 합류한 Ginkgo Bioworks Holdings Inc의 Chief Executive Officer입니다.
DNA 주식의 가격 성능은 어떻습니까?
DNA의 현재 가격은 $11.41이며, 전 거래일에 decreased 1.52% 하였습니다.
Ginkgo Bioworks Holdings Inc의 주요 사업 주제나 업종은 무엇입니까?
Ginkgo Bioworks Holdings Inc은 Life Sciences Tools & Services 업종에 속하며, 해당 부문은 Health Care입니다
Ginkgo Bioworks Holdings Inc의 시가총액은 얼마입니까?
Ginkgo Bioworks Holdings Inc의 현재 시가총액은 $641.4M입니다
Ginkgo Bioworks Holdings Inc는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 4명의 분석가가 Ginkgo Bioworks Holdings Inc에 대한 분석 평가를 실시했으며, 이는 0명의 강력한 매수, 1명의 매수, 2명의 보유, 5명의 매도, 그리고 0명의 강력한 매도를 포함합니다
